NDAORAL-21TABLET
Lifecycle
Pre-Launch
Data completeness
1/8 — Limited
NORLESTRIN 21 2.5/50 (ethinyl estradiol; norethindrone acetate) by Pfizer. Approved for pregnancy.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORLESTRIN 21 2.5/50 is a combined oral contraceptive tablet containing ethinyl estradiol and norethindrone acetate indicated for pregnancy prevention. It is a classic hormonal contraceptive that works by suppressing ovulation through estrogenic and progestagenic mechanisms. This pre-launch product represents Pfizer's entry into the mature oral contraceptive market with a higher-dose formulation.
Pre-Launch
Pre-launch status indicates active brand team buildout; commercial success will depend on differentiation against established competitors in a price-sensitive market.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Career Relevance
Working on NORLESTRIN 21 2.5/50 offers exposure to a pre-launch brand buildout within a mature, price-competitive therapeutic area. Success will require differentiation against entrenched competitors and generic-equivalent products, making this suitable for professionals skilled in market repositioning and managed care negotiation.
Brand Manager
Worked on NORLESTRIN 21 2.5/50 at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.